Malignant phenotype of PC3 cell line was inhibited by siRNA targeting PAR gene

Abstract

To investigate the effects of down-regulation of prostate androgen regulated (PAR) expression on proliferation of PC3 cells by using RNA interference (RNAi), suppression of PAR expression was achieved by transfection of PC3 cells with short hairpin RNA (shRNA) expression vectors against PAR, designated as psiRNA-PAR1, psiRNA-PAR2 and psiRNA-PAR3. The inhibitory effects were confirmed by RT-PCR. The growth features of PC3 transfectants were analyzed by cell counts, colon formation in soft agar and flow cytometry. The expression of PAR was suppressed by the three shRNA expression vectors. psiRNA-PAR1 was shown to inhibit the PAR expression most efficiently, with the inhibitory rate reaching a peak at (81.18±1.68)% 48 h after the transfection. PC3 transfectants exhibited a decreased proliferation in cell culture and a low efficiency of colon formation in soft agar. Flow cytometry revealed a G₂/M arrest and induced apoptosis. Down-regulated PAR expression inhibited the growth of PC3 cells by inducing G₂/M arrest and activating apoptotic pathway. As a potential proto-oncogene that triggers and/or has persistent malignant proliferation, PAR may serves as a very target for the gene therapy.

Keywords

PAR gene / prostate cancer / RNA interference / cell cycle / apoptosis

References

[1] GreenleeR. T., Hill-HarmonM. B., MurrayT., et al.. Cancer statistics. CA Cancer J Clin, 2001, 51(1): 15-36

[2] HegemanR. B., LiuG., WildingG., et al.. Newer therapies in advanced prostate cancer. Clin Prostate Cancer, 2004, 3(3): 150-156

[3] MiyamotoH., MessingE.M., ChangC.. Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate, 2004, 61(4): 332-353

[4] ShiX. B., GumerlockP. H., de-Vere WhiteR. W.. Molecular biology of prostate cancer. World J Urol, 1996, 14: 318-328

[5] HuncharekM., MuscatJ.. Genetic characteristics of prostate cancer. Cancer Epidemiol Biomarkers Prev, 1995, 4: 581-687

[6] PlaticaO., ChenS., IvanE., et al.. PAR, a novel androgen regulated gene, ubiquitously expressed in normal and malignant cells. Int J Oncol, 2000, 16(5): 1055-1061

[7] PlaticaM., IvanE., IonescuA., et al.. Transformation of NIH3T3 cells by enhanced PAR expression. Biochem Biophys Res Commun, 2004, 314: 891-896

[8] SituZ. Q., WuJ. Z.. Cell Culture, 2004, Xi’an, World Publishing Corporation: 249-250

[9] WeiW., GongJ. P., QiuF. Z.. Selection and comparison of flow cytomytry methods for cell apoptosis quantitative analysis. Acta Univ Med Tongji, 1999, 28(3): 181-184

[10] BonaccorsiL., MuratoriM., CarloniV., et al.. Androgen receptor and prostate cancer invasion. Int J Androl, 2003, 26(1): 21-25

[11] HorvathL. G., HenshallS. M., KenchJ. G., et al.. Loss of BMP2, Smad8 and Smad4 expression in prostate cancer progression. Prostate, 2004, 59(3): 234-242

[12] BrummelkampT. R., BernardsR., AgamiR.. A system for stable expression of short interfering RNAs in mammalian cells. Science, 2002, 296: 550-553

[13] ReynoldsA., LeakeD., BoeseQ., et al.. A. Rational siRNA design for RNA interference. Nat Biotechnol, 2004, 22(3): 326-330

[14] SohailM., DoranG., RiedemannJ., et al.. A simple and cost-effective method for producing small interfering RNAs with high efficacy. Nucleic Acids Res, 2003, 31(7): e38

[15] MesterovaM., Cho-ChungY. S.. Killing the messenger: antisense DNA and siRNA. Curr Drug Targets, 2004, 5(8): 683-689

[16] LabaziM., PhillipsA. C.. Oncogenes as regulators of apoptosis. Essays Biochem, 2003, 39: 89-104

[17] VermeulenK., BernemanZ. N., Van BockstaeleD. R.. Cell cycle and apoptosis. Cell Prolif, 2003, 36(3): 165-175